2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

NCT00090246 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

922

Enrollment

INDUSTRY

Sponsor class

Conditions

Postoperative Nausea and Vomiting

Interventions

DRUG: MK0869, aprepitant
DRUG: Comparator: ondansetron IV

Sponsor

Merck Sharp & Dohme LLC